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Summary  Although  calcium  channel  blockers  have  been  reported  to  aggravate  Brugada-type
electrocardiogram  (ECG)  abnormalities,  there  have  been  few  reports  in  clinical  settings.  WeBrugada  syndrome;
Calcium  channel
blockers;
Diltiazem;
present a  case  of  Brugada  syndrome  coexisting  with  vasospastic  angina,  in  whom  Brugada-type
ST-segment  elevation  was  aggravated  and  ventricular  ﬁbrillation  attacks  occurred  by  calcium
channel blocker  treatment.  When  prescribing  calcium  channel  blockers  to  patients  with  Brugada
syndrome,  it  is  important  to  pay  careful  attention  to  changes  in  their  ECG  pattern.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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Introduction
Brugada  syndrome  is  one  of  the  causes  of  sudden  cardiac
death,  which  is  characterized  by  a  peculiar  electrocardio-
gram  (ECG)  pattern  consisting  of  a  pseudo-right  bundle
branch  block  and  ST-segment  elevation  in  leads  V1  to  V3.
Vasospastic  angina  (VSA)  can  also  cause  sudden  cardiac
death  [1],  and  the  coexistence  of  Brugada  syndrome  and
VSA  has  been  reported  previously  [2,3]. Calcium  channel
blockers  (Ca  blockers)  are  the  ﬁrst-choice  drugs  for  treat-
ing  VSA.  Ca  blockers  have  been  reported  to  suppress  lethal
arrhythmia  in  patients  with  VSA  [1].  On  the  other  hand,
Ca  blockers,  especially  verapamil,  have  been  reported  to
aggravate  Brugada-type  ECG  abnormalities  [4—9], but  there
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doi:10.1016/j.jccase.2011.09.001ave  been  few  reports  [8,9]  in  clinical  settings.  We  report  a
atient  in  whom  Brugada  syndrome  and  VSA  were  found  to
oexist  and  in  whom  Brugada-type  ST-segment  elevation  was
ggravated  and  ventricular  ﬁbrillation  (VF)  attacks  occurred
y  Ca  blocker  treatment.
ase report
 39-year-old  man  was  admitted  to  our  hospital  for  fur-
her  examination  after  successful  resuscitation  from  cardiac
rrest.
He  had  suffered  convulsions  and  collapsed  while  sleep-
ng  early  in  the  morning  after  drinking  alcohol.  After  the
rrival  of  the  ambulance,  an  ECG  monitor  detected  VF.  The
F  was  successfully  terminated  via  the  application  of  a
irect  current  shock  with  an  automated  external  deﬁbrilla-
or.  Soon  after  the  patient’s  heartbeat  had  returned  to  sinus
Published by Elsevier Ltd. All rights reserved.
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Figure  1  An  electrocardiogram  (ECG)  monitor  after  the  termination  of  ventricular  ﬁbrillation  (A)  and  12-lead  ECGs  on  admission
(B, C).  An  ECG  monitor  (A)  soon  after  recovery  from  cardiac  arrest  showed  elevation  of  the  ST-segment.  A  12-lead  ECG  (B)  showed
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Vo Brugada-type  ST-segment  elevation,  but  an  ECG  in  high  ches
n lead  V2  (arrow).
hythm,  an  ECG  monitor  showed  elevation  of  the  ST-segment
Fig.  1A).  He  recovered  without  any  neurological  deﬁcits  and
as  referred  to  our  department  for  further  examinations  of
he  cause  of  his  cardiac  arrest.
He  had  no  history  of  syncope  or  chest  pain  and  no  family
istory  of  sudden  death.  He  had  not  been  taking  any  drugs
ntil  the  above  event  occurred.
He  was  admitted  to  our  hospital  11  days  after  being
esuscitated.  On  admission,  neither  physical  nor  neuro-
ogical  abnormalities  were  observed.  Laboratory  analysis
nd  chest  X-rays  were  normal.  Transthoracic  echocardio-
rams  showed  a  normal  cardiac  structure.  A  12-lead  ECG
howed  no  Brugada-type  ST-segment  elevation,  but  an  ECG
n  high  chest  leads  revealed  type  2  saddle  back-type  ST
egment  elevation  in  lead  V2  (Fig.  1B,  C).  A  Holter  ECG
howed  no  abnormalities,  and  treadmill  exercise  stress  test-
ng  showed  negative  results  for  myocardial  ischemia  and
he  induction  of  arrhythmia.  Late  potential  was  negative
n  signal  averaged  ECG.  We  considered  VSA  as  a  differen-
ial  diagnosis  because  the  pattern  of  the  12-lead  ECG  did
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(ds  (C)  revealed  type  2  saddle  back-type  ST  segment  elevation
ot  match  the  typical  Brugada  ECG  pattern  and  because
ardiac  arrest  occurred  early  in  the  morning  after  drink-
ng  alcohol.  Thus,  cardiac  catheterization  was  performed.
 coronary  angiogram  showed  no  signiﬁcant  stenosis.  Dif-
use  coronary  spasms  were  induced  in  both  the  right  and  left
oronary  arteries  by  ergonovine  maleate  injection  (Fig.  2),
lthough  they  were  not  accompanied  by  signiﬁcant  ST-T
hanges.  An  electrophysiological  study  was  performed.  VF
as  not  induced  by  the  single,  double,  or  triple  extra-
timuli  to  the  right  ventricular  apex  and  outﬂow  tract.
he  intravenous  injection  of  pilsicainide  (50  mg)  caused
ype  1  coved-type  ST-segment  elevation  in  the  precordial
eads.
The  patient  met  the  diagnostic  criteria  for  Brugada  syn-
rome,  and  the  coexistence  of  VSA  was  highly  suspected.
SA  has  been  reported  to  be  accompanied  by  Brugada
yndrome,  both  of  which  can  cause  VF.  Therefore,  an
mplantable  cardioverter-deﬁbrillator  (ICD)  was  implanted
s  a  treatment  for  his  Brugada  syndrome,  and  diltiazem
100  mg/day)  was  prescribed  to  treat  his  VSA.
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 no  si
e  ma
i
o
d
c
i
i
i
r
i
V
t
i
c
w
e
e
c
V
p
VFigure  2  Coronary  angiograms.  A  coronary  angiogram  showed
in both  the  left  (C)  and  right  (D)  coronary  arteries  by  ergonovin
Two  weeks  after  he  had  been  discharged,  the  patient
experienced  seven  ICD  shocks  while  sleeping  early  in  the
morning.  All  episodes  involved  VF,  and  the  ICD  worked  appro-
priately.  An  ECG  monitor  in  the  ICD  showed  no  ST-segment
changes  before  or  after  the  VF  attack.  Follow-up  ECG  using
the  high  chest  leads  showed  type  1  coved-type  ST-segment
elevation  (Fig.  3).  According  to  experimental  studies  [4—6],
Ca  blockers  have  been  reported  to  aggravate  Brugada-type
ST-segment  elevation  by  decreasing  the  inward  currents  in
the  epicardium  in  a  similar  manner  to  sodium  channel  block-
ers.  As  there  was  a  possibility  that  diltiazem  had  induced  VF
attacks  in  this  case,  its  administration  was  discontinued  and
nitrate  treatment  was  started.  After  the  diltiazem  had  been
discontinued,  no  further  VF  attacks  occurred,  and  the  type
1  coved-type  ST-segment  elevation  disappeared  (Fig.  3).
Discussion
This  case  was  diagnosed  as  symptomatic  Brugada  syndrome
from  the  patient’s  history  of  sudden  cardiac  arrest  and  type
1  coved-type  ST-segment  elevation  in  pilsicainide-induced
ECG.  On  the  other  hand,  the  coexistence  of  VSA  was  sus-
pected  from  the  induction  of  diffuse  coronary  spasms  in  both
the  right  and  left  coronary  arteries  by  ergonovine  maleate
t
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bgniﬁcant  stenosis  (A,  B).  Diffuse  coronary  spasms  were  induced
leate  injection.
njection.  Chinushi  et  al.  [2]  reported  that  the  coexistence
f  VSA  was  recognized  in  13.1%  of  patients  with  Brugada  syn-
rome.  Both  Brugada  syndrome  and  VSA  can  cause  sudden
ardiac  death  [1].  In  addition,  they  also  show  other  sim-
larities;  i.e.  the  incidences  of  the  two  diseases  are  high
n  relatively  young  men,  and  they  are  associated  with  an
mbalance  between  sympathetic  and  parasympathetic  tone,
esulting  in  high  incidence  early  in  the  morning.  Therefore,
n  cases  involving  the  coexistence  of  Brugada  syndrome  and
SA,  it  may  be  difﬁcult  to  decide  which  of  the  two  condi-
ions  is  the  direct  cause  of  sudden  cardiac  arrest,  resulting
n  treatments  being  administered  for  both  as  we  did  in  this
ase.
The  ﬁrst-choice  medication  for  VSA  is  Ca  blockers,  and
e  prescribed  diltiazem  (100  mg/day)  in  this  case.  Several
xperimental  studies  [4—6]  have  reported  that  Ca  block-
rs,  as  well  as  other  drugs  such  as  sodium  channel  blockers,
an  aggravate  Brugada-type  ECG  abnormalities  and  induce
F  attacks.  However,  there  are  few  reports  [8,9]  about
atients  who  showed  aggravation  of  Brugada-type  ECG  and
F  attacks  with  Ca  blocker  in  clinical  settings.  According
o  a  previous  report  [2],  a  low  dose  of  Ca  blockers  neither
orsens  Brugada-type  ECG  abnormalities  nor  increases  the
requency  of  VF  attacks.  However,  the  susceptibility  to  Ca
lockers  may  differ  among  individuals  [7,10]. In  our  case,
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Figure  3  Follow-up  electrocardiograms  (ECGs).  After  the  diltiazem  treatment  was  started  (A),  follow-up  ECG  in  high  chest  leads
showed type  1  coved-type  ST-segment  elevation  in  leads  V1  and  V2  (arrow).  After  the  diltiazem  treatment  had  been  discontinued
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RB), the  type  1  coved-type  ST-segment  elevation  in  leads  V1  and
n high  chest  leads.
he  dose  of  diltiazem  (100  mg/day)  used  was  the  same  as
s  applied  in  general  clinical  practice,  but  it  aggravated
he  Brugada-type  ECG  abnormalities.  Ca  blockers  work  on
oth  myocardium  and  smooth  muscles  of  vessels.  Verapamil
orks  on  the  myocardium  predominantly.  According  to  a
revious  reports  [2,8,9], we  can  recognize  that  verapamil
an  aggravate  Brugada-type  ECG  abnormalities.  Diltiazem  is
ne  of  the  antiarrhythmic  drugs  like  verapamil  and  also  has
 strong  effect  on  myocardium,  therefore  there  was  a pos-
ibility  that  the  continuation  of  diltiazem  treatment  would
ave  increased  the  risk  of  lethal  arrhythmia.  Diltiazem  was
iscontinued,  and  treatment  with  a  nitrate  was  started.  It
s  well  known  that  Brugada-type  ECG  abnormalities  spon-
aneously  ﬂuctuate  on  a  day-to-day  basis  and  depend  on
he  patient’s  condition.  Therefore,  it  cannot  be  stated  that
iltiazem  was  directly  related  to  the  aggravation  of  ECG
bnormalities  or  VF  facilitation  in  this  case.  However,  the
atient’s  Brugada-type  ST-segment  elevation  was  alleviated
nd  no  VF  attacks  occurred  after  the  diltiazem  treatment
as  discontinued.isappeared  (asterisk).  Normal,  normal  12-lead  ECG;  High,  ECG
The present  case  suggests  that  when  prescribing  Ca
lockers  for  patients  with  Brugada  syndrome,  we  should
ecognize  that  lethal  arrhythmia  can  be  induced  even  with
 dose  of  general  clinical  use  and  should  perform  care-
ul  follow-up  to  detect  changes  in  the  ECG  pattern.  When
rugada-type  ECG  abnormalities  are  aggravated  after  the
tart  of  treatment  with  Ca  blockers,  we  have  to  consider
hanging  the  patient’s  medication.
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